Immunome Inc. (IMNM)
| Bid | 9.7 |
| Market Cap | 855.22M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -7.94 |
| PE Ratio (ttm) | -1.27 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.11 |
| Volume | 418,217 |
| Avg. Volume (20D) | 971,623 |
| Open | 9.90 |
| Previous Close | 9.90 |
| Day's Range | 9.63 - 10.12 |
| 52-Week Range | 8.97 - 30.96 |
| Beta | undefined |
About IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 a...
Analyst Forecast
According to 5 analyst ratings, the average rating for IMNM stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 197.03% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
3 weeks ago · seekingalpha.com
Immunome Can Take The Fight To Competitors With VaregacestatImmunome Can Take The Fight To Competitors With Varegacestat
3 weeks ago · businesswire.com
Immunome Announces Pricing of Upsized Public Offering of Common StockBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
2 months ago · businesswire.com
Immunome to Present at the Piper Sandler 36th Annual Healthcare ConferenceBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome'...